Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1219-1225

  Higano, Celestia S ^a,f   Vogelzang, Nicholas J ^b   Sosman, Jeffrey A ^c   Feng, Anyang ^d   Caron, Dania ^d   Small, Eric J ^e  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT HUMAN FLT3 LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE SCINTISCANNING; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION PAIN; MALE; NATURAL KILLER CELL; NOCTURIA; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS, HORMONAL; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 1642353525     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1404-02     Document Type: Article

References (32)

1. Lyman, S. D., Johnson, J. L., Brasel, K., de Vries, P., Escobar, S. S., et al. Cloning of the human homologue of the murine Flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood, 83: 2795-2801, 1994.
2. McKenna, H. J., de Vries, P., Brasel, K., Lyman, S. D., and Williams, D. E. The effect of Flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood, 86: 3413-3420, 1995.
3. Winton, E. F., Bucur, S. Z., Bray, R. A., Toba, K., Williams, D. E., and McClure, H. M. The hematopoietic effects of recombinant human (rh) Flt3 ligand administered to non-human primates. Blood, 86: 424a, 1995.
4. Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med., 184: 1953-1962, 1996.
5. Maraskovsky, E., Daro, E., Roux, E., Teepe, M., Maliszewski, C. R., Hoek, J., Caron, D., Lebsack, M. E., and McKenna, H. J. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood, 96: 878-884, 2000.
6. Morse, M. A., Nair, S., Fernandez-Casal, M., Deng, Y., St Peter, M., Williams, R., et al. Preoperative mobilization of circulating dendritic cells by flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol., 18: 3883-3893, 2000.
7. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
8. McKenna, H. J. Generating a T cell tumor-specific immune response in vivo: can flt3 ligand generated dendritic cells tip the balance? Cancer Immunol. Immunother., 48: 281-286, 1999.
9. Cohen, P. J., Cohen, P. A., Rosenberg, S. A., Katz, S. I., and Mule, J. J. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol., 24: 315-319, 1994.
10. Flamand, V. T., Sornasse, K., Thielemans, C., Demanet, C., Bakkus, M., Bazin, H., et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol., 24: 605-610, 1994.
11. Celluzzi, C. M., Mayordomo, J. I., and Storkus, W. J. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med., 183: 283-287, 1996.
12. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol., 156: 2918-2926, 1996.
13. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.
14. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A., and Carbone, D. P. Dendritic cells in antitumor immune responses: dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol., 170: 111-119, 1996.
15. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
16. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
17. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., Deleo, A. B., Clarke, M. R., Lotze, M. T., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
18. Nestle, F., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
19. Lynch, D. H., Andreasen, A., Miller, R. E., and Schuh, J. C. C. Flt3 ligand: a novel dendritic cell (DC)-stimulating cytokine that induces tumor regression and anti-tumor immune responses in vivo. Blood, 80 (Suppl. 1): 437a, 1996.
20. Lyman, S. D., and Jacobsen, S. E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood, 91: 1101-1134, 1998.
21. Ajani, J. A., Welch, S. R., Raber, M. N., Fields, W. S., and Krakoff, I. H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investig., 8: 147-159, 1990.
22. Vollmer, R. T., Dawson, N. A., and Vogelzang, N. J. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer (Phila.), 83: 1989-1994, 1998.
23. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA, 96: 2233-2238, 1999.
24. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
25. Lord, E. M., and Frelinger, J. G. Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol. Immunother., 46: 75-81, 1998.
26. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
27. Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma a feasibility study. Blood, 93: 2411-2419, 1999.
28. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Ragde, H., Rogers, M., Elgamal, A., et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate, 39: 54-59, 1999.
29. Holtl, L., Rieser, C., Papesh, C., Ramoner, R., Herold, M., Klocker, H., et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol., 161: 777-782, 1999.
30. Morse, M. A., Coleman, R. E., Akabani, G., Niehaus, N., Coleman, D., and Lyerly, H. K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 59: 56-58, 1999.
31. Rissoan, M., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., de Waal Malefyt, R., Liu, Y. J. Reciprocal control of T helper cell and dendritic cell differentiation. Science (Wash. DC), 283: 1183-1186, 1999.
32. Pulendran, B., Burkeholder, S., Kraus, E., Guinet, E., Fay, J., Davoust, J., Caron, D., et al. Differential mobilization of distinct DC subsets in vivo by flt3-ligand and G-CSF. Blood, 94 (Suppl. 1): 213a, 1999.